In particular immune checkpoint inhibitors of cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell-death receptor 1 (PD-1)/programmed cell-death ligand 1 (PD-L1) have been approved for various types of metastatic cancers [4]. This evidence concerns the gene CD274 and metastatic malignant neoplasm.